ZDHHC9 and familial pancreatic carcinoma: Likewise, in pancreatic cancer models, ZDHHC9 overexpression was linked to impaired anti-tumor immunity, whereas knocking down ZDHHC9 converted the TME from immunosuppressive to immune-active and improved treatment responses (32).